Comparative Pharmacology
Head-to-head clinical analysis: BLISOVI FE 1 5 30 versus NORTREL 1 35 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLISOVI FE 1 5 30 versus NORTREL 1 35 21.
BLISOVI FE 1.5/30 vs NORTREL 1/35-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Blisovi Fe 1.5/30 is a combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). It inhibits ovulation via suppression of gonadotropins (FSH and LH). Additionally, it increases cervical mucus viscosity, impeding sperm penetration, and alters endometrial development, reducing implantation likelihood.
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, altering cervical mucus to impede sperm penetration, and inducing endometrial changes that reduce implantation likelihood.
One tablet orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets (iron-free).
One tablet orally once daily for 21 days, followed by 7 days off, then repeat.
None Documented
None Documented
Ethinyl estradiol: terminal half-life ~17 hours (range 13–27 h) with single dose; for norethindrone: ~8–11 hours. Clinical context: Steady-state achieved within ~7–10 days; contraceptive efficacy maintained with once-daily dosing.
Norethindrone: 5-14 hours; Ethinyl estradiol: 17-24 hours. Steady-state achieved after 10 days.
Renal: ~60% (ethinyl estradiol metabolites as glucuronide/sulfate conjugates, norethindrone metabolites). Fecal: ~40% (biliary excretion of conjugates, with some enterohepatic recirculation).
Renal 50-60% as metabolites, fecal 40-50% as conjugates, <1% unchanged
Category C
Category C
Oral Contraceptive
Oral Contraceptive